METHODS FOR PREVENTING AND TREATING INTRA-ABDOMINAL CANDIDIASIS
Provided herein are methods of identifying an individual having or at risk of developing intra-abdominal candidiasis (IAC) and treating, mitigating, or preventing IAC in the individual by administering a pharmaceutical composition including CD101, in salt or neutral form, in an amount sufficient to effectively treat or prevent IAC.
1 . A method of treating an individual having intra-abdominal candidiasis (IAC), comprising:
(i) identifying the individual as having IAC or suspected as having IAC; and
(ii) administering to the individual a pharmaceutical composition comprising CD101 in salt or neutral form, wherein said composition is sufficient to treat the IAC.
2 . A method of preventing IAC in an individual at risk thereof, comprising:
(i) identifying the individual as being at risk of developing IAC; and
(ii) administering to the individual a pharmaceutical composition comprising CD101 in salt or neutral form, wherein said composition is sufficient to prevent the development of IAC.
3 . The method of claim 1 , wherein the subject has an intra-abdominal abscess (IAA) and wherein the pharmaceutical composition is administered to the individual at a dosage and frequency sufficient for the concentration of CD101 within the IAA to exceed the mutant prevention concentration (MPC) of CD101 for Candida.
4 . The method of claim 3 , wherein the concentration of CD101 within the IAA achieves a concentration that exceeds the MPC within 6 hours following administration.
5 . The method of claim 3 , wherein the concentration of CD101 within the IAA is maintained at a concentration that exceeds the MPC for at least 24 hours.
6 . The method of claim 5 , wherein the concentration of CD101 within the IAA is maintained at a concentration that exceeds the MPC for at least 48 hours.
7 . The method of claim 6 , wherein the concentration of CD101 within the IAA is maintained at a concentration that exceeds the MPC for at least 72 hours.
8 . The method of claim 3 , wherein the MPC is 1 μg/ml to 30 μg/ml.
9 . The method of claim 8 , wherein the MPC is about 16 μg/ml.
10 . The method of claim 1 , wherein the pharmaceutical composition is administered subcutaneously, intra-abdominally, or intravenously.
11 . The method of claim 1 , wherein the pharmaceutical composition is administered weekly for one to twelve weeks in an amount of 200 to 1200 mg.
12 . The method of claim 1 , wherein the pharmaceutical composition is administered is administered to the subject in a single dose, wherein the single dose comprises an amount of the CD101 in salt or neutral form sufficient to treat IAC.